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We would like to thank the authors of the letter for their perti-
nent comments on our manuscript. We fully agree that CLI treat-
ment cannot be accomplished by surgery alone and recognise the
importance of postoperative care, including wound management
and medication. In our manuscript, we emphasise that healing
ischaemic wounds is not easy, even after successful revasculariza-
tion, because of the impaired wound healing ability and impaired
immune system of compromised patients, such as those with dia-
betes or end-stage renal disease (ESRD).
As mentioned in the manuscript, we employ negative pressure
wound therapy (NPWT) for most deep wounds to facilitate granu-
lation formation. NPWT is one of greatest advances in the ﬁeld of
wound management and may contribute to shortened ulcer heal-
ing time.1 Conversely, hyperbaric oxygen therapy (HBO) is not
used routinely in our institution because of its inaccessibility.
Further randomised studies are required to evaluate whether
HBO has beneﬁts even in revascularised feet. To stimulate cell
growth and accomplish complete epithelialisation, a recombinant
ﬁbroblast growth factor (FGF) spray was applied to most of patient
wounds. Although, in this study, more than several months were
required to heal ischaemic ulcers in patients with ESRD despite
employing NPWT and the FGF spray, new bioengineered technolo-
gies for stimulating angiogenesis and new advancedwound healing
technologies are expected.2
Currently, there is no clear recommendation for postoperative
medication in CLI patients that is supported by strong evidence.
A portion of our patients (25%) experienced critically low graft
ﬂow as a result of poor run-off. To improve the microcirculation
and increase graft ﬂow, those patients underwent a prosta-
glandin E1 infusion through the vein graft. While all patients
were postoperatively administrated antiplatelet agents, cilosta-
zole was selected to 38% of patients to prevent progressive
vein graft intimal hyperplasia and life-threatening cardiovascular
events.
Further basic and clinical studies are required to examine post-
operative standard care and to improvewound healing and the QOL
of CLI patients.References
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doi:10.1016/j.ejvs.2012.04.003Antegradly Performed TEVARWe congratulate the authors for their work on the incidence of
stroke in thoracic endovascular aortic replacement (TEVAR) due to
arcus aorta aneursyms.1 We wonder if TEVAR,performed in 32
patients in whom zone 0 was intervened, was performed in the
same sitting with surgical intervention to ascending aorta. We
would like to know how TEVAR was performed if TEVAR was
carried out in the same session. That’s because if TEVAR is per-
formed in the same session as surgical procedure it can be done
antegradely from ascending aorta rather than the retrograde tech-
nique in which femoral artery is utilized. In this technique a 8-mm
graft is anastomosed to ascending aorta or the graft interposed to
ascending aorta. TEVAR is performed antegradely with this 8-mm
graft.2 Performing this procedure by antegrade route provides
such advantages as avoiding complications likely to develop in
the iliofemoral artery used as the site of access during the proce-
dure and ensuring sufﬁcient length in order for the endograft
deployment systems to reach the landing zones.2,3 Moreover, pres-
ence of shorter carrier systems in the antegrade approach will
cause delivery of less rotational power, thus providing maximum
precision in the placement of the graft. Another advantage is that
antegrade approach permits manual manipulations of the endog-
raft in order to ﬁt it to a desired position in the aortic arch, thanks
to the open sternum.2,3 Apart from that, there appears to be a risk of
entering the false lumen in the femoral or iliac arteries upon using
the retrograde route especially in dissection cases. Under the light
of this knowledge we feel that it is essential to keep in mind that
TEVAR can be antegradely done too, particularly in cases with
thoracic aorta aneursyms where sternum is opened.
